Browse Category

Investment News News 30 December 2025

Verizon stock today: VZ edges up as DOJ DEI probe headline hangs over telecom ahead of Jan. 30 earnings

Verizon stock today: VZ edges up as DOJ DEI probe headline hangs over telecom ahead of Jan. 30 earnings

NEW YORK, December 30, 2025, 15:17 ET — Regular session Verizon Communications Inc shares were up 0.5% at $40.69 in afternoon trading on Tuesday, bucking a mostly flat U.S. market as investors digested new regulatory scrutiny and looked ahead to the carrier’s next earnings update. Reuters The latest headline matters because legal and compliance risk can move quickly for large government contractors, and telecoms are already grappling with intense competition and heavy capital spending. Any shift in policy pressure can influence costs, disclosures and management attention. Reuters It also lands during year-end, low-liquidity trading, when relatively small flows can push
Applied Materials stock slips as China’s 50% domestic chip-tool rule puts AMAT in the spotlight

Applied Materials stock slips as China’s 50% domestic chip-tool rule puts AMAT in the spotlight

NEW YORK, December 30, 2025, 15:20 ET — Regular session Applied Materials, Inc. (AMAT.O) shares slipped on Tuesday, with investors weighing fresh signs of tougher competition in China for semiconductor equipment makers. The stock was down 1.1% at $260.27 in mid-afternoon New York trade. The stock drew attention after Reuters reported China is requiring chipmakers seeking approval to build or expand fabs to use at least 50% domestically made equipment when adding new capacity. The measure is not publicly documented and is enforced through procurement tenders, people familiar with the matter told Reuters, and authorities can relax the threshold where
Qualcomm stock edges up as Fed minutes hit; QCOM eyes Feb. 4 earnings call

Qualcomm stock edges up as Fed minutes hit; QCOM eyes Feb. 4 earnings call

NEW YORK, December 30, 2025, 15:14 ET — Regular session Qualcomm (QCOM.O) shares were up about 0.2% at $173.75 in afternoon trading on Tuesday, hovering near Monday’s close as markets digested new details on the U.S. interest-rate outlook. That matters for Qualcomm and other semiconductor names because investors often value them like “growth” stocks, whose prices can swing when bond yields move. In year-end trading, the rate narrative can outweigh company-specific headlines. Minutes from the Federal Reserve’s Dec. 9-10 meeting — the detailed account of policymakers’ debate — showed officials split even after approving a quarter-point, or 0.25 percentage point,
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key swing factors for the stock heading into 2026. Biotech stocks lagged, with the iShares Nasdaq Biotechnology ETF down about 1.1%, while the healthcare sector ETF was roughly flat and the S&P 500 ETF hovered near unchanged. Verastem Oncology said it
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

NEW YORK, December 30, 2025, 13:50 ET — Regular session Pfizer Inc (NYSE:PFE) shares were up about 0.1% at $25.03 in afternoon trading on Tuesday, after moving between $24.92 and $25.10. TD Cowen reiterated its Hold rating and kept a $30 price target, pointing to negative trends in its model through 2030 despite the stock’s dividend yield near 7%. Investing.com The call lands as investors weigh Pfizer’s latest 2026 targets after the drugmaker projected revenue of $59.5 billion to $62.5 billion next year and adjusted earnings of $2.80 to $3.00 a share. “Adjusted” earnings strip out certain items the company
ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

NEW YORK, December 30, 2025, 13:35 ET — Regular session Shares of ADMA Biologics fell 3.7% to $18.40 in afternoon trading on Tuesday, a steeper drop than the broader biotech group. The SPDR S&P Biotech ETF was down about 1.3%. The pullback came as U.S. stocks steadied in holiday-thin trading ahead of minutes from the Federal Reserve’s December policy meeting, after the central bank delivered a 25-basis-point cut this month. Mark Hackett, chief market strategist at Nationwide, described recent positioning as “a healthy rebalancing of allocations.” Reuters Biotechnology shares were among the laggards, with the NYSE Arca Biotechnology Index down
Silver price today: SLV jumps nearly 7% as silver rebounds after record-high rout

Silver price today: SLV jumps nearly 7% as silver rebounds after record-high rout

NEW YORK, December 30, 2025, 13:30 ET — Regular session Silver prices rebounded on Tuesday after a sharp pullback from record highs, pushing the iShares Silver Trust (SLV) up about 6.9% in New York trade. Spot silver was up 4.7% at $76.38 an ounce at 11:29 a.m. ET, a day after touching an all-time high of $83.62 and suffering its biggest one-day drop since August 2020. Analysts at Societe Generale pointed to CME Group’s move on Friday to raise the initial margin requirement for silver futures — the cash traders must post to hold positions — as a factor behind
Vipshop stock slides about 5% today as Jefferies flags softer December trends ahead of Fed minutes

Vipshop stock slides about 5% today as Jefferies flags softer December trends ahead of Fed minutes

NEW YORK, December 30, 2025, 1:14 PM ET — Regular session Vipshop Holdings Limited (VIPS) shares fell about 5% on Tuesday, trading around $18.39 in afternoon dealings. The drop came in a muted U.S. session with year-end liquidity thin, leaving single-stock swings more pronounced than usual. Reuters Investors are also waiting for the Federal Reserve’s minutes from its Dec. 9-10 meeting due later Tuesday, looking for signals on how policymakers see the 2026 path for interest rates. Reuters Jefferies analyst Thomas Chong reiterated a buy rating and a $22.60 price target on Vipshop. Jefferies expects fourth-quarter revenue at the low
Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

NEW YORK, December 30, 2025, 12:44 ET — Regular session Johnson & Johnson shares edged lower on Tuesday after the company said it completed its $3.05 billion cash purchase of cancer-therapy developer Halda Therapeutics. The stock was down about 0.2% at $207.12 in midday trading. Executive vice president Jennifer Taubert called the closing a “strategic milestone” as J&J flagged about $0.20 of dilution to adjusted earnings per share — profit per share excluding certain one-time items — split between 2025 and 2026. Johnson & Johnson Investor Relations The closing gives J&J a new platform aimed at developing oral, targeted cancer
IAMGOLD (IAG) stock rises as gold rebounds from margin-driven selloff; Fed minutes ahead

IAMGOLD (IAG) stock rises as gold rebounds from margin-driven selloff; Fed minutes ahead

NEW YORK, December 30, 2025, 12:44 ET — Regular session Shares of IAMGOLD Corporation (NYSE: IAG) rose about 2.3% to $16.86 by 12:44 p.m. ET on Tuesday, tracking a rebound in bullion after a sharp pullback a day earlier. The stock was up from Monday’s close of $16.48 and traded between $16.48 and $16.99. The move matters because gold miners have been whipsawed into year-end, with prices reacting quickly to shifts in precious metals and investor positioning. In Canada, mining shares helped push the TSX higher on Tuesday as gold and silver recovered, while investors waited for fresh signals from
AST SpaceMobile stock jumps 6% today as launch cadence and insider buy lift sentiment

AST SpaceMobile stock jumps 6% today as launch cadence and insider buy lift sentiment

NEW YORK, December 30, 2025, 12:19 ET — Regular session Shares of AST SpaceMobile (ASTS) rose 6.5% to $76.09 in midday trading on Tuesday, after the satellite-to-smartphone firm and one of its carrier partners flagged progress toward a larger constellation. The stock opened at $72.10 and traded between $72.07 and $78.27, with about 10.6 million shares changing hands. The rally matters because AST is trying to prove it can deliver “direct-to-device” service — a satellite link that works with standard smartphones without special hardware — and investors are using each launch and testing milestone as a readout on execution. Reuters
PSLV stock pops as silver rebounds from record-high whipsaw; Fed minutes in focus

PSLV stock pops as silver rebounds from record-high whipsaw; Fed minutes in focus

NEW YORK, December 30, 2025, 11:51 ET — Regular session. Sprott Physical Silver Trust rose 4.4% to $25.33 in late-morning trade on Tuesday, after swinging between $24.58 and $25.45. The trust’s U.S.-listed units were up $1.06 from Monday’s close, with volume around 9.8 million shares. The move put PSLV back in step with the metal it holds after a sudden bout of volatility jolted the silver market into year-end. For investors who use exchange-traded products as a liquid proxy for bullion, the last two sessions have been a reminder that leverage and liquidity can matter as much as the macro
1 115 116 117 118 119 215

Stock Market Today

Stellantis stock rattled by $26.5 billion EV reset and dividend halt ahead of Monday trade

Stellantis stock rattled by $26.5 billion EV reset and dividend halt ahead of Monday trade

7 February 2026
Milan, February 7, 2026, 10:54 (CET) — Market closed. Stellantis shares (STLA) closed at $7.28 in New York on Friday, down 23.8%, after the Jeep maker unveiled a €22.2 billion ($26.5 billion) hit tied to scaling back electric-vehicle plans and said it would not pay a dividend in 2026. The selloff matters going into next week because it forces a quick rethink on cash and capital returns at a company investors once treated as a high-yield play. With markets shut for the weekend, traders will be looking for any follow-through from credit markets and analysts before Monday’s open. In Europe,
Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop